当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Richard Feynman*
Pharmacogenomics, a field at the intersection of pharmacology and genomics, aims to uncover how an individual’s genetic makeup influences their response to drugs. By studying genetic variations that affect drug metabolism and efficacy, pharmacogenomics holds great promise for optimizing drug selection and dosage, thereby improving treatment outcomes and minimizing adverse effects. This article provides an overview of pharmacogenomics, its applications in personalized medicine, and the challenges associated with its implementation. Pharmacogenomics focuses on analyzing how an individual’s genetic variations affect drug response, metabolism, and toxicity. Genetic variations, known as single nucleotide polymorphisms (SNPs), can occur in genes encoding drug-metabolizing enzymes, drug targets, or transporters. These SNPs can lead to interindividual differences in drug efficacy and safety. The field of pharmacogenomics employs advanced technologies such as genome-wide association studies (GWAS) and next-generation sequencing (NGS) to identify genetic variants associated with drug response. Through these studies, researchers aim to establish predictive biomarkers that can guide clinicians in tailoring drug therapies based on an individual’s genetic profile.